ARCHIVES

NCI, FDA Near Agreement On INDs; Young, Hoogstraten Clash On Rubidazone

This article is from The Cancer Letter archive.

Vol. 03 No. 02 | January 14, 1977

Download PDF Visit The Full Archive

Related Articles

Center Program Move Definite; DCBD to Be Renamed

September 22, 1989

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

September 30, 2011

Diane Fink Accepts VP Job With ACS

April 3, 1981

NCI-Approved Protocols Listed

December 26, 2003

Rauscher Disappointed In CREG Progress

October 1, 1976